---
title: "SOLIGENIX, INC. 3Q 2026: Revenue $0 EPS $(0.12) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295273764.md"
description: "Soligenix reported Q3 2026 results with $0 revenue and a net loss of $(1.99M), or $(0.12) EPS, an improvement from the prior year. The company terminated its HyBryte program but highlighted positive Phase 2a results for SGX945 and SGX302. ThermoVax demonstrated stability, and multiple regulatory designations were granted. Soligenix expects cash runway into Q2 2028 via grants and equity sales."
datetime: "2026-08-07T20:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295273764.md)
  - [en](https://longbridge.com/en/news/295273764.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295273764.md)
generator: "portal-rs"
---

# SOLIGENIX, INC. 3Q 2026: Revenue $0 EPS $(0.12) — 10-Q Summary

SOLIGENIX, INC. reported results for the third quarter ended June 30, 2026, posting no revenue and a net loss applicable to common stockholders of $(1.99M), or a basic and diluted loss per share of $(0.12), an improvement versus the year-ago quarter.

**Financial Highlights**

-   Revenue was $0 for the three months ended June 30, 2026, unchanged from the prior-year quarter.
-   Net income: Net loss applicable to common stockholders of $(1,987,354) for the three months ended June 30, 2026, improved from a loss of $(2,701,976) in the year-ago quarter.
-   Diluted EPS: Basic and diluted net loss per share of $(0.12) for the three months ended June 30, 2026, versus $(0.82) in the year-ago quarter.

**Business Highlights**

-   Pipeline changes: The board terminated the HyBryte™ (CTCL) program after the FLASH2 study was halted for futility, and the company is refocusing resources on other candidates.
-   Clinical progress: Completed a positive Phase 2a study of SGX945 in Behçet’s disease; SGX302 Phase 2a showed biological and clinical benefit.
-   Vaccine platform: ThermoVax® demonstrated multi-year thermostability and nonhuman primate protection for bivalent/trivalent filovirus vaccine candidates.
-   Funding and operations: Continued reliance on government grants/contracts and at-the-market equity sales to fund operations; company expects cash runway into Q2 2028.
-   Regulatory designations: Multiple orphan, Fast Track and PIM designations were granted for SGX945, RiVax®, filovirus and MARV/SUDV assets.

Original SEC Filing: SOLIGENIX, INC. \[ SNGX \] - 10-Q - Aug. 07, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SNGX.US](https://longbridge.com/en/quote/SNGX.US.md)

## Related News & Research

- [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md)
- [PicS Q2 2026 Earnings Preview](https://longbridge.com/en/news/296709997.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md)
- [Northrop Grumman announces R$ 0.17 per unit dividend for Q3 2026](https://longbridge.com/en/news/296645808.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**